Market Closed

NVCR
NovoCure Limited
$ 11.83
0.94%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago

NovoCure Limited News

Latest NovoCure Limited Stock News & NVCR Headlines

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
2 days ago | businesswire.com
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
5 days ago | fool.com
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
6 days ago | businesswire.com
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
13 days ago | zacks.com
NovoCure: 3 Key Takeaways for Long-Term Investors
14 days ago | fool.com
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
17 days ago | seekingalpha.com
NovoCure Q3 Earnings Call Highlights
17 days ago | marketbeat.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
17 days ago | zacks.com
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
18 days ago | businesswire.com
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast
a month ago | defenseworld.net
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

NVCR
NovoCure Limited
$ 11.83
0.94%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago